


PHARMACEUTICAL 2023



Dianthus Therapeutics Inc. DE Rank 192 of 446





PHARMACEUTICAL 2023



Dianthus Therapeutics Inc. DE Rank 192 of 446

The relative strengths and weaknesses of Dianthus Therapeutics Inc. DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dianthus Therapeutics Inc. DE compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 36% points. The greatest weakness of Dianthus Therapeutics Inc. DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 41% points.

The company's Economic Capital Ratio, given in the ranking table, is 113%, being 70% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	115,602
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,549
Liabilities, Non-Current	26,138
Other Assets	24,948
Other Compr. Net Income	-151
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	4,440
Property and Equipment	6,095
Research and Development	55,141
Selling, General and Administrative Expense	25,761

Output Variable	Value in 1000 USD
Assets	146,645
Liabilities	40,687
Expenses	80,902
Revenues	4,440
Stockholders Equity	105,958
Net Income	-76,462
Comprehensive Net Income	-76,538
Economic Capital Ratio	113%

